NASDAQ · FENC
Fennec Pharmaceuticals Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for FENC: Nov 12, 2026
Fennec Pharmaceuticals Inc. Common Stock is estimated to report earnings on 11/12/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 4 analysts' forecasts, the consensus EPS forecast for the quarter is $0.09. The reported EPS for the same quarter last year was $-0.02.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $0.09 | $0.14 | $0.06 | 4 |
| Dec 2026 | $0.12 | $0.16 | $0.09 | 4 |
| Mar 2027 | $0.14 | $0.18 | $0.11 | 3 |
| Jun 2027 | $0.20 | $0.25 | $0.16 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Zacks · MarketBeat · The Motley Fool- RTTNews · Sep 17, 10:23 AM EDTFennec To Present Detailed Phase 2 Pedmark Data From STS-J01 Study At SIOP 2026(RTTNews) – Fennec Pharmaceuticals Inc. (FENC) announced that detailed results from the investigator-initiated Phase 2 STS-J01 clinical study evaluating Pedmark in Japanese pediatric patients will be presented orally at the SIOP 2026 Annual Congress in Washington, D.C., on Octobe
- Zacks · Aug 12, 9:55 AM EDTCan Adherex Technologies (FENC) Climb 26.53% to Reach the Level Wall Street Analysts Expect?The mean of analysts' price targets for Adherex Technologies (FENC) points to a 26.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- MarketBeat · Aug 11, 11:05 AM EDTAdherex Technologies Q2 Earnings Call HighlightsAdherex Technologies (NASDAQ:FENC), operating as Fennec Pharmaceuticals, reported second-quarter 2026 net product sales of $17.1 million, up approximately 78% from $9.7 million in the prior-year period, as demand for its PEDMARK therapy continued to rise. Chief Executive Officer
- RTTNews · Aug 11, 10:31 AM EDTFennec Pharmaceuticals' Q2 Sales Surge 78%; Adjusted EBITDA Turns Positive(RTTNews) – Fennec Pharmaceuticals Inc. (FENC), a specialty pharmaceutical company focused on developing and commercializing therapies for patients with cancer, has announced its financial results for the second quarter ended June 30, 2026.
- Zacks · Aug 11, 8:20 AM EDTAdherex Technologies Inc. (FENC) Beats Q2 Earnings and Revenue EstimatesAdherex Technologies (FENC) delivered earnings and revenue surprises of +400.00% and +11.73%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Aug 10, 5:10 PM EDTSepterna, Inc. (SEPN) Reports Q2 Loss, Beats Revenue EstimatesSepterna, Inc. (SEPN) delivered earnings and revenue surprises of +39.58% and +30.07%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- RTTNews · Aug 10, 5:49 AM EDTBiotech Stocks At 52-Week Highs – HALO +20% On Q2 Results, FENC, AVLN, AMLX, CHE(RTTNews) – The following biotech stocks reached 52-week highs on August 7, 2026, driven by key catalysts such as positive quarterly reports or upcoming clinical results.
- Zacks · Jul 6, 1:21 PM EDTIs the Options Market Predicting a Spike in Adherex Technologies Stock?Investors need to pay close attention to FENC stock based on the movements in the options market lately.
- MarketBeat · May 23, 10:05 AM EDTAdherex Technologies’ PEDMARK Push Targets Larger AYA Market After Record QuarterFennec Pharmaceuticals (NASDAQ:FENC) executives outlined the company’s commercial strategy for PEDMARK, its sodium thiosulfate product used to prevent cisplatin-related hearing loss, during a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference. Ram Sel
- The Motley Fool · May 14, 2:43 PM EDTFennec (FENC) Q1 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- Zacks · May 14, 11:32 AM EDTDo Options Traders Know Something About Adherex Technologies Stock We Don't?Investors need to pay close attention to FENC stock based on the movements in the options market lately.
- MarketBeat · May 14, 11:06 AM EDTAdherex Technologies Q1 Earnings Call HighlightsAdherex Technologies (NASDAQ:FENC) executives said Fennec Pharmaceuticals entered 2026 with stronger commercial momentum for PEDMARK, reporting higher first-quarter sales, positive operating cash flow and early signs that recent sales force investments are increasing demand. On
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Fennec Pharmaceuticals Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.